Biogen’s high-stakes Alzheimer’s gamble is being roasted by the experts. Is the amyloid beta theory dead?

Biogen {$BIIB} and its partners at Eisai had hoped to breathe some new life into the increasingly wobbly amyloid beta theory for theory for Alzheimer’s when they sounded an upbeat note about their latest data cut on BAN2401. Instead, the controversy over the trial design in the face of growing doubts about researchers’ insistence about their success has only beaten down expectations that anything can work here. And the bleak outlook is also infecting Biogen’s odds of success for their critically important program for aducanumab.

[caption id="attachment_30706" align="alignright" width="140"] Geoffrey Porges, Leerink[/caption]

Leerink’s Geoffrey Porges led the funeral parade in a note out this morning, citing two “leading academic Alzheimer’s disease” KOLs who are backing even further away from the developers' drugs, lowering already slim chances of success and dousing the amyloid beta theory in ways that will haunt everyone still focused on their chances here. And that’s a notable group of players.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 48,100+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 48,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->